Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Brodmann, M; Keirse, K; Scheinert, D; Spak, L; Jaff, MR; Schmahl, R; Li, P; Zeller, T; IN.PACT Global Study Investigators.
Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
JACC Cardiovasc Interv. 2017; 10(20):2113-2123 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Brodmann Marianne
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
This study sought to evaluate the safety and effectiveness of a paclitaxel-coated drug-coated balloon (DCB) for the treatment of patients with de novo in-stent restenosis (ISR). Treatment of patients with ISR remains a challenge. Current strategies are plagued by high rates of recurrent restenosis and need for reintervention. The best intervention for ISR remains to be elucidated. The IN.PACT Global study is an independently adjudicated multicenter, prospective, single-arm study that enrolled 1,535 subjects with symptomatic atherosclerotic disease of the superficial femoral and/or popliteal arteries, including de novo ISR lesions. Patients enrolled in the pre-specified ISR imaging cohort were evaluated for vessel patency and reintervention within the 12-month follow-up period. A total of 131 subjects with 149 ISR lesions were included for analysis. The mean age of the cohort was 67.8 years. Mean lesion length was 17.17 ± 10.47 cm, including 34.0% total occlusions and 59.1% calcified lesions. The 12-month Kaplan-Meier estimate of primary patency was 88.7%. The rate of clinically driven target lesion revascularization (CD TLR) at 12 months was 7.3%. The primary safety outcome, a composite of freedom from device- and procedure-related mortality through 30 days and freedom from major target limb amputation and CD TLR within 12 months, was 92.7%. There were no major target limb amputations, no deaths, and a low (0.8%) thrombosis rate. Results from the ISR imaging cohort demonstrate high patency and a low rate of CD TLR at 12 months. These data confirm the safety and effectiveness of the IN.PACT Admiral DCB (Medtronic, Dublin, Ireland) in complex femoropopliteal lesions, including this challenging subset. Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Amputation -
Angiography -
Angioplasty, Balloon - adverse effects
Angioplasty, Balloon - instrumentation
Angioplasty, Balloon - mortality
Cardiovascular Agents - administration & dosage
Cardiovascular Agents - adverse effects
Coated Materials, Biocompatible -
Constriction, Pathologic -
Endovascular Procedures - adverse effects
Endovascular Procedures - instrumentation
Endovascular Procedures - mortality
Female -
Femoral Artery - diagnostic imaging
Femoral Artery - physiopathology
Humans -
Kaplan-Meier Estimate -
Limb Salvage -
Male -
Middle Aged -
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Peripheral Arterial Disease - diagnostic imaging
Peripheral Arterial Disease - mortality
Peripheral Arterial Disease - physiopathology
Peripheral Arterial Disease - therapy
Popliteal Artery - diagnostic imaging
Popliteal Artery - physiopathology
Prospective Studies -
Recurrence -
Stents -
Time Factors -
Treatment Outcome -
Ultrasonography, Doppler, Duplex -
Vascular Access Devices -
Vascular Patency -

Find related publications in this database (Keywords)
drug-coated balloon
femoropopliteal artery
in-stent restenosis
paclitaxel
peripheral artery disease
© Meduni Graz Impressum